CDC Website CDC Website

To Join the NPIN community or

Home » Adipogenesis, Adipocyte Function and Obesity Following HIV Infection, Antiretroviral Therapy, or Pre-Exposure Prophylaxis (R01 Clinical Trial Optional)

Adipogenesis, Adipocyte Function and Obesity Following HIV Infection, Antiretroviral Therapy, or Pre-Exposure Prophylaxis (R01 Clinical Trial Optional)

The prevalence of obesity is increasing in people with HIV (PWH), contributing to multiple complications associated with this condition. There is mounting evidence that there are unique mechanisms contributing to the development of obesity in PWH versus people without HIV. Furthermore, the biology of the adipocytes might be altered in overweight or obese PWH versus overweight or obese people without HIV. This FOA seeks applications to elucidate the underlying mechanisms of how HIV and antiretroviral drugs used for therapy or pre-exposure prophylaxis contribute to the development of obesity and alter adipocyte and adipose tissue function as well as the effects of these processes on metabolic and physiological processes within the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). 

Application Due Date
11/7/19
Project Start Date
7/1/20
Application Contact
Ms. Jeni
Smits
Senior Grants Management Specialist
United States
301-827-4020
jeni.smits@nih.gov
Technical Contact
Peter
J.
Perrin, Ph.D.
Program Director
peter.perrin@nih.gov
United States
301-451-3759
Subjects
Audiences
Focus Area

Fund Number: 

5483

Fund ID: 

RFA-DK-19-008

Last Updated: 

6/4/19